Valuation: ConvaTec Group

Market Cap 5.7B 4.98B 4.6B 4.24B 7.99B 549B 8.16B 54.95B 21.61B 269B 21.41B 20.94B 926B P/E 2026 *
20.7x
P/E 2027 * 16.2x
Enterprise Value 6.9B 6.03B 5.56B 5.13B 9.67B 664B 9.88B 66.51B 26.16B 325B 25.91B 25.35B 1,120B EV / Sales 2026 *
2.69x
EV / Sales 2027 * 2.46x
Free-Float
95.19%
Yield 2026 *
2.69%
Yield 2027 * 3.01%
Manager TitleAgeSince
Chief Executive Officer 62 04/08/2025
Director of Finance/CFO 51 04/08/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 71 14/08/2017
Chairman 78 30/09/2019
Director/Board Member 62 02/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5.62B
+1.87%+7.19%-16.46%-5.91% 172B
-0.43%-0.80%-7.07%-4.05% 107B
-0.03%+1.47%+4.59%+60.25% 59.92B
+0.66%+0.96%+37.56%+53.38% 51.58B
-1.10%+4.10%-12.56%-38.37% 44.07B
-3.21%-3.05% - - 34.76B
-1.71%+2.25%-8.86%-44.23% 30.09B
-1.16%+1.28%+61.67%-6.62% 25.61B
-1.49%+0.85%-3.01%-4.60% 21.55B
Average -0.66%+1.64%+6.98%+1.23% 60.74B
Weighted average by Cap. +0.06%+2.77%-1.33%+3.17%

Financials

2026 *2027 *
Net sales 2.57B 2.24B 2.07B 1.91B 3.6B 247B 3.68B 24.74B 9.73B 121B 9.64B 9.43B 417B 2.74B 2.39B 2.21B 2.03B 3.84B 264B 3.92B 26.39B 10.38B 129B 10.28B 10.06B 444B
Net income 276M 241M 223M 205M 387M 26.61B 396M 2.66B 1.05B 13.03B 1.04B 1.01B 44.86B 359M 313M 289M 267M 502M 34.53B 514M 3.46B 1.36B 16.91B 1.35B 1.32B 58.22B
Net Debt 1.2B 1.05B 967M 892M 1.68B 116B 1.72B 11.56B 4.55B 56.58B 4.51B 4.41B 195B 1.03B 904M 834M 769M 1.45B 99.61B 1.48B 9.97B 3.92B 48.78B 3.88B 3.8B 168B
Logo ConvaTec Group
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA